{"id":"penicillin-g-sodium","_fda":{"id":"0e84343e-8796-4c54-8dcc-8448a231fcfa","set_id":"23b6d4a3-b273-4e10-9da9-1376933fdbdf","openfda":{"unii":["YS5LY7JF4N"],"route":["INTRAMUSCULAR","INTRAVENOUS"],"rxcui":["745302"],"spl_id":["0e84343e-8796-4c54-8dcc-8448a231fcfa"],"brand_name":["Penicillin G Sodium"],"spl_set_id":["23b6d4a3-b273-4e10-9da9-1376933fdbdf"],"package_ndc":["0781-6153-94","0781-6153-95","0781-6153-97"],"product_ndc":["0781-6153"],"generic_name":["PENICILLIN G SODIUM"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["PENICILLIN G SODIUM"],"manufacturer_name":["Sandoz Inc"],"application_number":["ANDA065068"],"is_original_packager":[true]},"version":"15","warnings":["WARNINGS SERIOUS AND OCCASIONALLY FATAL HYPERSENSITIVITY (anaphylactic) REACTIONS HAVE BEEN REPORTED IN PATIENTS ON PENICILLIN THERAPY. THESE REACTIONS ARE MORE LIKELY TO OCCUR IN INDIVIDUALS WITH A HISTORY OF PENICILLIN HYPERSENSITIVITY AND/OR A HISTORY OF SENSITIVITY TO MULTIPLE ALLERGENS. THERE HAVE BEEN REPORTS OF INDIVIDUALS WITH A HISTORY OF PENICILLIN HYPERSENSITIVITY WHO HAVE EXPERIENCED SEVERE REACTIONS WHEN TREATED WITH CEPHALOSPORINS. BEFORE INITIATING THERAPY WITH PENICILLIN G, CAREFUL INQUIRY SHOULD BE MADE CONCERNING PREVIOUS HYPERSENSITIVITY REACTIONS TO PENICILLINS, CEPHALOSPORINS, OR OTHER ALLERGENS. IF AN ALLERGIC REACTION OCCURS, PENICILLIN G SHOULD BE DISCONTINUED AND APPROPRIATE THERAPY INSTITUTED. SERIOUS ANAPHYLACTIC REACTIONS REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE. OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including penicillin G sodium, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile . C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated."],"pregnancy":["Pregnancy Teratogenic Effects Reproduction studies performed in the mouse, rat, and rabbit have revealed no evidence of impaired fertility or harm to the fetus due to penicillin G. Human experience with the penicillins during pregnancy has not shown any positive evidence of adverse effects on the fetus. There are, however, no adequate and well controlled studies in pregnant women showing conclusively that harmful effects of these drugs on the fetus can be excluded. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed."],"overdosage":["OVERDOSAGE Dose related toxicity may arise with the use of massive doses of intravenous penicillins (40 to 100 million units per day), particularly in patients with severe renal impairment (see PRECAUTIONS ). The manifestations may include agitation, confusion, asterixis, hallucinations, stupor, coma, multifocal myocionus, seizures and encephalopathy. Hypernatremia is also possible (see ADVERSE REACTIONS: Metabolic ). In case of over-dosage, discontinue penicillin, treat symptomatically and institute supportive measures as required. If necessary, hemodialysis may be used to reduce blood levels of penicillin G, although the degree of effectiveness of this procedure is questionable."],"description":["DESCRIPTION Penicillin G sodium for Injection, USP is sterile penicillin G sodium powder for reconstitution. It is an antibacterial agent intended for intravenous or intramuscularly use. Chemically, penicillin G sodium is designated 4-Thia-1-azabicyclo(3.2.0)-heptane-2-carboxylic acid,3,3-dimethyl-7-oxo-6-[(phenylacetyl)amino]-, [2 S -(2α, 5α, 6β)]-, monosodium salt and has the following structural formula: Penicillin G sodium, a water soluble benzylpenicillin, is a white to almost white crystalline powder which is almost odorless and/or after reconstitution a colorless solution. The pH of freshly constituted solutions usually ranges from 5.0 to 7.5. Penicillin G sodium for Injection, USP is supplied in vials equivalent to 5,000,000 units (5 million units) of penicillin G as the sodium salt, with 1.68 mEq of sodium per million units of penicillin G. chemical-structure"],"precautions":["PRECAUTIONS General Penicillin should be used with caution in individuals with histories of significant allergies and/or asthma (see WARNINGS ). Whenever allergic reactions occur, penicillin should be withdrawn unless, in the opinion of the physician, the condition being treated is life-threatening and amenable only to penicillin therapy. Penicillin G Sodium for injection, USP by the intravenous route in high doses (above 10 million units) should be administered slowly because of the potential adverse effects of electrolyte imbalance from the sodium content of the penicillin. Penicillin G Sodium for injection, USP contains 1.68 mEq of sodium per million units of penicillin G. The use of antibiotics may promote overgrowth of nonsusceptible organisms, including fungi. Indwelling intravenous catheters encourage superinfections. Should superinfection occur, appropriate measures should be taken. When indicated, incision and drainage or other surgical procedures should be performed in conjunction with antibiotic therapy. Prescribing penicillin G sodium in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. Laboratory Tests Periodic assessment of organ system function, including frequent evaluation of electrolyte balance, hepatic, renal and hematopoietic systems, and cardiac and vascular status should be performed during prolonged therapy with high doses of intravenous penicillin G (see ADVERSE REACTIONS ). If any impairment of function is suspected or known to exist, a reduction in the total dosage should be considered (see DOSAGE AND ADMINISTRATION ). In suspected staphylococcal infections, proper laboratory studies, including susceptibility tests should be performed. All infections due to Group A beta-hemolytic streptococci should be treated for at least 10 days. Patients being treated for gonococcal infection should have a serologic test for syphilis before receiving penicillin. All cases of penicillin treated syphilis should receive adequate follow-up including clinical and serological examinations. The recommended follow-up varies with the stage of syphilis being treated. See CDC recommendations. Drug Interactions Bacteriostatic antibacterials (i.e., chloramphenicol, erythromycins, sulfonamides or tetracyclines) may antagonize the bactericidal effect of penicillin, and concurrent use of these drugs should be avoided. This has been documented in vitro, however, the clinical significance of this interaction is not well-documented. Penicillin blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of penicillins. Other drugs may compete with Penicillin G for renal tubular secretion and thus prolong the serum half-life of penicillin. These drugs include: aspirin, phenylbutazone, sulfonamides, indomethacin, thiazide diuretics, furosemide and ethacrynic acid. Drug/Laboratory Test Interactions After treatment with penicillin G, a false-positive reaction for glucose in the urine may occur with Benedict’s solution, Fehling’s solution or Clinitest® tablet, but not with the enzyme-based tests, such as Clinistix® and Tes-Tape®. Penicillin G has been associated with pseudoproteinuria by certain test methods. Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term animal studies have been conducted with this drug. Pregnancy Teratogenic Effects Reproduction studies performed in the mouse, rat, and rabbit have revealed no evidence of impaired fertility or harm to the fetus due to penicillin G. Human experience with the penicillins during pregnancy has not shown any positive evidence of adverse effects on the fetus. There are, however, no adequate and well controlled studies in pregnant women showing conclusively that harmful effects of these drugs on the fetus can be excluded. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Nursing Mothers Penicillins are excreted in human milk. Caution should be exercised when penicillins are administered to a nursing woman. Pediatric Use lncompletely developed renal function in newborns may delay elimination of penicillin; therefore, appropriate reductions in the dosage and frequency of administration should be made in these patients. All newborns treated with penicillins should be monitored closely for clinical and laboratory evidence of toxic or adverse effects (see PRECAUTIONS ). Pediatric doses are generally determined on a weight basis and should be calculated for each patient individually. Recommended guidelines for pediatric dosages are presented in DOSAGE AND ADMINISTRATION . The potential for toxic effects in children from chemicals that may leach from the single dose premixed intravenous preparation in plastic containers has not been evaluated. Information for Patients Patients should be counseled that antibacterial drugs including penicillin G sodium should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When penicillin G sodium is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by penicillin G sodium or other antibacterial drugs in the future. Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible."],"how_supplied":["HOW SUPPLIED Penicillin G Sodium for injection, USP, for IM or IV use, is supplied in dry powder form in vials containing 5,000,000 units (5 million units) of crystalline penicillin G as the sodium salt, with 1.68 mEq of sodium per million units of penicillin G, in tray packs of 10 (NDC 0781-6153-95) and in tray packs of 50 (NDC 0781-6153-97). STORAGE Store dry powder at 20° to 25°C (68° to 77°F) (see USP Controlled Room Temperature). Sterile constituted solution may be kept in refrigerator (2° to 8°C) for 3 days without significant loss of potency. Manufactured by Sandoz GmbH for Sandoz Inc., Princeton, NJ 08540 46270951 May 2020"],"pediatric_use":["Pediatric Use lncompletely developed renal function in newborns may delay elimination of penicillin; therefore, appropriate reductions in the dosage and frequency of administration should be made in these patients. All newborns treated with penicillins should be monitored closely for clinical and laboratory evidence of toxic or adverse effects (see PRECAUTIONS ). Pediatric doses are generally determined on a weight basis and should be calculated for each patient individually. Recommended guidelines for pediatric dosages are presented in DOSAGE AND ADMINISTRATION . The potential for toxic effects in children from chemicals that may leach from the single dose premixed intravenous preparation in plastic containers has not been evaluated."],"effective_time":"20200527","nursing_mothers":["Nursing Mothers Penicillins are excreted in human milk. Caution should be exercised when penicillins are administered to a nursing woman."],"laboratory_tests":["Laboratory Tests Periodic assessment of organ system function, including frequent evaluation of electrolyte balance, hepatic, renal and hematopoietic systems, and cardiac and vascular status should be performed during prolonged therapy with high doses of intravenous penicillin G (see ADVERSE REACTIONS ). If any impairment of function is suspected or known to exist, a reduction in the total dosage should be considered (see DOSAGE AND ADMINISTRATION ). In suspected staphylococcal infections, proper laboratory studies, including susceptibility tests should be performed. All infections due to Group A beta-hemolytic streptococci should be treated for at least 10 days. Patients being treated for gonococcal infection should have a serologic test for syphilis before receiving penicillin. All cases of penicillin treated syphilis should receive adequate follow-up including clinical and serological examinations. The recommended follow-up varies with the stage of syphilis being treated. See CDC recommendations."],"adverse_reactions":["ADVERSE REACTIONS Body as a Whole The Jarisch-Herxheimer reaction is a systemic reaction, that may occur after the initiation of penicillin therapy in patients with syphilis or other spirochetal infections (i.e., Lyme disease and Relapsing fever). The reaction begins one to two hours after initiation of therapy and disappears within 12 to 24 hours. It is characterized by fever, chills, myalgias, headache, exacerbation of cutaneous lesions, tachycardia, hyperventiliation, vasodilation with flushing and mild hypotension. The pathogenesis of the Herxheimer reaction may be due to the release from the spirochaete of host stable pyrogen. Hypersensitivity Reactions The reported incidence of allergic reactions to all penicillins ranges from 0.7 to 10 percent in different studies (see WARNINGS ). Sensitization is usually the result of previous treatment with a penicillin, but some individuals have had immediate reactions when first treated. In such cases, it is postulated that prior exposure to penicillin may have occurred via trace amounts present in milk or vaccines. Two types of allergic reactions to penicillin are noted clinically – Immediate and delayed. Immediate reactions usually occur within 20 minutes of administration and range in severity from urticaria and pruritus to angloneurotic edema, laryngospasm, bronchospasm, hypotension, vascular collapse and death (see WARNINGS ). Such immediate anaphylactic reactions are very rare and usually occur after parenteral therapy, but a few cases of anaphylaxis have been reported following oral therapy. Another type of immediate reaction, an accelerated reaction, may occur between 20 minutes and 45 hours after administration and may include urticaria, pruritus, fever and, occasionally, laryngeal edema. Delayed reactions to penicillin therapy usually occur within 1 to 2 weeks after initiation of therapy. Manifestations include serum sickness-like symptoms, i.e., fever, malaise, urticaria, myalgia, arthralgia, abdominal pain and various skin rashes, ranging from maculopapular eruptions to exfoliative dermatitis. Contact dermatitis has been observed in individuals who prepare penicillin solutions. Gastrointestinal System Pseudomembranous colitis has been reported with the onset occurring during or after penicillin G treatment. Nausea, vomiting, stomatitis, black or hairy tongue, and other symptoms of gastrointestinal irritation may occur, especially during oral therapy. Hematologic System Reactions include neutropenia, which resolves after penicillin therapy is discontinued; Coombs-positive hemolytic anemia, an uncommon reaction, occurs in patients treated with intravenous penicillin G in doses greater than 10 million units/day and who have previously received large doses of the drug; and with large doses of penicillin, a bleeding diathesis, can occur secondary to platelet dysfunction. Metabolic Penicillin G Sodium for injection, USP (1 million units contains 1.68 mEq of sodium ion) may cause serious and even fatal electrolyte disturbances when given intravenously in large doses. Cardiovascular System High dosage of penicillin G sodium may result in congestive heart failure due to high sodium intake. Nervous System Neurotoxic reactions including hyperreflexia, myoclonic twitches, seizures and coma have been reported following the administration of massive intravenous doses, and are more likely in patients with impaired renal function. Urogenital System Renal tubular damage and interstitial nephritis have been associated with large intravenous doses of penicillin G. Manifestations of this reaction may include fever, rash, eosinophilia, proteinuria, eosinophiluria, hematuria and a rise in serum urea nitrogen. Discontinuation of penicillin G results in resolution in the majority of patients. Local Reactions Phlebitis and thrombophlebitis may occur with intravenous administration."],"contraindications":["CONTRAINDICATIONS A history of hypersensitivity (anaphylactic) reaction to any penicillin is a contraindication."],"drug_interactions":["Drug Interactions Bacteriostatic antibacterials (i.e., chloramphenicol, erythromycins, sulfonamides or tetracyclines) may antagonize the bactericidal effect of penicillin, and concurrent use of these drugs should be avoided. This has been documented in vitro, however, the clinical significance of this interaction is not well-documented. Penicillin blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of penicillins. Other drugs may compete with Penicillin G for renal tubular secretion and thus prolong the serum half-life of penicillin. These drugs include: aspirin, phenylbutazone, sulfonamides, indomethacin, thiazide diuretics, furosemide and ethacrynic acid."],"general_precautions":["General Penicillin should be used with caution in individuals with histories of significant allergies and/or asthma (see WARNINGS ). Whenever allergic reactions occur, penicillin should be withdrawn unless, in the opinion of the physician, the condition being treated is life-threatening and amenable only to penicillin therapy. Penicillin G Sodium for injection, USP by the intravenous route in high doses (above 10 million units) should be administered slowly because of the potential adverse effects of electrolyte imbalance from the sodium content of the penicillin. Penicillin G Sodium for injection, USP contains 1.68 mEq of sodium per million units of penicillin G. The use of antibiotics may promote overgrowth of nonsusceptible organisms, including fungi. Indwelling intravenous catheters encourage superinfections. Should superinfection occur, appropriate measures should be taken. When indicated, incision and drainage or other surgical procedures should be performed in conjunction with antibiotic therapy. Prescribing penicillin G sodium in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria."],"teratogenic_effects":["Teratogenic Effects Reproduction studies performed in the mouse, rat, and rabbit have revealed no evidence of impaired fertility or harm to the fetus due to penicillin G. Human experience with the penicillins during pregnancy has not shown any positive evidence of adverse effects on the fetus. There are, however, no adequate and well controlled studies in pregnant women showing conclusively that harmful effects of these drugs on the fetus can be excluded. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed."],"storage_and_handling":["STORAGE Store dry powder at 20° to 25°C (68° to 77°F) (see USP Controlled Room Temperature). Sterile constituted solution may be kept in refrigerator (2° to 8°C) for 3 days without significant loss of potency. Manufactured by Sandoz GmbH for Sandoz Inc., Princeton, NJ 08540 46270951 May 2020"],"clinical_pharmacology":["CLINICAL PHARMACOLOGY After an intravenous infusion of penicillin G, peak serum concentrations are attained immediately after completion of the infusion. In a study of ten patients administered a single 5 million unit dose of penicillin G intravenously over 3 to 5 minutes, the mean serum concentrations were 400 mcg/mL, 273 mcg/mL and 3 mcg/mL at 5 to 6 minutes, 10 minutes and 4 hours after completion of the injection, respectively. In a separate study, five healthy adults were administered one million units of penicillin G intravenously, either as a bolus over 4 minutes or as an infusion over 60 minutes. The mean serum concentration eight minutes after completion of the bolus was 45 mcg/mL and eight minutes after completion of the infusion was 14.4 mcg/mL. The mean β-phase serum half-life of penicillin G administered by the intravenous route in ten patients with normal renal function was 42 minutes, with a range of 31 to 50 minutes. The clearance of penicillin G in normal individuals is predominantly via the kidney. The renal clearance, which is extremely rapid, is the result of glomerular filtration and active tubular transport, with the latter route predominating. Urinary recovery is reported to be 58 to 85% of the administered dose. Renal clearance of penicillin is delayed in premature infants, neonates and in the elderly due to decreased renal function. The serum half-life of penicillin G correlates inversely with age and clearance of creatinine and ranges from 3.2 hours in infants 0 to 6 days of age to 1.4 hours in infants 14 days of age or older. Nonrenal clearance includes hepatic metabolism and, to a lesser extent, biliary excretion. The latter routes become more important with renal impairment. Probenecid blocks the renal tubular secretion of penicillin. Therefore, the concurrent administration of probenecid prolongs the elimination of penicillin G and, consequently, increases the serum concentrations. Penicillin G is distributed to more areas of the body including lung, liver, kidney, muscle, bone and placenta. In the presence of inflammation, levels of penicillin in abscesses, middle ear, pleural, peritoneal and synovial fluids are sufficient to inhibit most susceptible bacteria. Penetration into the eye, brain, cerebrospinal fluid (CSF) or prostate is poor in the absence of inflammation. With inflamed meninges, the penetration of penicillin G into the CSF improves, such that the CSF/serum ratio is 2 to 6%. Inflammation also enhances its penetration into the pericardial fluid. Penicillin G is actively secreted into the bile resulting in levels at least 10 times those achieved simultaneously in serum. Penicillin G penetrates poorly into human polymorphonuclear leukocytes. In the presence of impaired renal function, the β-phase serum half-life of penicillin G is prolonged. β-phase serum half-lives of one to two hours were observed in azotemic patients with serum creatinine concentrations <3 mg/100 mL and ranged as high as 20 hours in anuric patients. A linear relationship, including the lowest range of renal function, is found between the serum elimination rate constant and renal function as measured by creatinine clearance. In patients with altered renal function, the presence of hepatic insufficiency further alters the elimination of penicillin G. In one study, the serum half-lives in two anuric patients (excreting <400 mL urine/day) were 7.2 and 10.1 hours. A totally anuric patient with terminal hepatic cirrhosis had a penicillin half-life of 30.5 hours, while another patient with anuria and liver disease had a serum half-life of 16.4 hours.The dosage of penicillin G should be reduced in patients with severe renal impairment, with additional modifications when hepatic disease accompanies the renal impairment. Hemodialysis has been shown to reduce penicillin G serum levels. Microbiology Penicillin G is bactericidal against penicillin-susceptible microorganisms during the stage of active multiplication. It acts by inhibiting biosynthesis of cell-wall mucopeptide. It is not active against the penicillinase-producing bacteria, which include many strains of staphylococci. Penicillin G is highly active in vitro against staphylococci (except penicillinase-producing strains), streptococci (groups A, B, C, G, H, L and M), pneumococci and Neisseria meningitidis. Other organisms susceptible in vitro to penicillin G are Neisseria gonorrhoeae, Corynebacterium diphtheriae, Bacillus anthracis, clostridia, Actinomyces species, Spirillum minus, Streptobacillus monillformis, Listeria monocytogenes, and leptospira; Treponema pallidum is extremely susceptible. Some species of gram-negative bacilli were previously considered susceptible to very high intravenous doses of penicillin G (up to 80 million units/day) including some strains of Escherichia coli, Proteus mirabilis, salmonella, shigella, Enterobacter aerogenes (formerly Aerobacter aerogenes ) and Alcaligenes faecalis. Penicillin G is no longer considered a drug of choice for infections caused by these organisms. Susceptibility Testing For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC."],"indications_and_usage":["INDICATIONS AND USAGE Therapy Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."],"information_for_patients":["Information for Patients Patients should be counseled that antibacterial drugs including penicillin G sodium should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When penicillin G sodium is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by penicillin G sodium or other antibacterial drugs in the future. Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible."],"spl_unclassified_section":["Rx Only To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Penicillin G Sodium for injection, USP may be given intravenously or intramuscularly. The usual dose recommendations are as follows: Adult Patients Clinical Indication Dosage Serious infections due to susceptible strains of streptococci (including S. pneumoniae ) and staphylococci-septicemia, empyema, pneumonia, pericarditis, endocarditis and meningitis 5 to 24 million units/day depending on the infection and its severity administered in equally divided doses every 4 to 6 hours Anthrax Minimum of 8 million units/day in divided doses every 6 hours. Higher doses may be required depending on susceptibility of organism. Actinomycosis Cervicofacial disease Thoracic and abdominal disease 1 to 6 million units/day(*) 10 to 20 million units/day(*) Clostridial infections Botulism (adjunctive therapy to antitoxin) Gas gangrene (debridement and/or surgery as indicated) Tetanus (adjunctive therapy to human tetanus immune globulin) 20 million units/day(*) Diphtheria (adjunctive therapy to antitoxin and for the prevention of the carrier state) 2 to 3 million units/day in divided doses for 10 to 12 days(*) Erysipelothrix endocarditis 12 to 20 million units/day for 4 to 6 weeks(*) Fusospirochetosis (severe infections of the oropharnyx [Vincent’s], lower respiratory tract and genital area) 5 to 10 million units/day(*) Listeria infections Meningitis Endocarditis 15 to 20 million units/day for 2 weeks(*) 15 to 20 million units/day for 4 weeks(*) Pasteurella infections including bacteremia and meningitis 4 to 6 million units/day for 2 weeks(*) Haverhill fever, Rat-bite fever 12 to 20 million units/day for 3 to 4 weeks(*) Disseminated gonococcal infections, such as meningitis endocarditis, arthritis, etc., caused by penicillin- susceptible organisms 10 million units/day(*); duration depends on the type of infection Syphilis (neurosyphilis) 12 to 24 million units/day, as 2 to 4 MU every 4 hours for 10 to 14 days; many experts recommend additional therapy with Benzathine PCN G 2.4 MU IM weekly for 3 doses after completion of IV therapy Meningococcal meningitis and/or septicemia 24 million units/day as 2 million units every 2 hours Serious infections, such as pneumonia and endocarditis, due to susceptible strains of streptococci (including S. pneumoniae ) and meningococcus 150,000 units/kg/day divided in equal doses every 4 to 6 hours; duration depends on infecting organism and type of infection Meningitis caused by susceptible strains of pneumococcus and meningococcus 250,000 units/kg/day divided in equal doses every 4 hours for 7 to 14 days depending on the infecting organism (maximum dose of 12 to 20 million units/day) Disseminated Gonococcal infections (penicillin-susceptible strains) weight less than 45 kg: Arthritis 100,000 units/kg/day in 4 equally divided doses for 7 to 10 days Meningitis 250,000 units/kg/day in equal doses every 4 hours for 10 to 14 days Endocarditis 250,000 units/kg/day in equal doses every 4 hours for 4 weeks Arthritis, meningitis, endocarditis weight 45 kg or greater: 10 million units/day in 4 equally divided doses with the duration of therapy depending on the type of infection Syphilis (congenital and neurosyphilis) after the newborn period 200,000 to 300,000 units/kg/day (administered as 50,000 units/kg every 4 to 6 hours) for 10 to 14 days Diphtheria (adjunctive therapy to antitoxin and for prevention of the carrier state) 150,000 to 250,000 units/kg/day in equal doses every 6 hours for 7 to 10 days Rat-bite fever; Haverhill fever (with endocarditis caused by S. moniliformis ) 150,000 to 250,000 units/kg/day in equal doses every 4 hours for 4 weeks *Because of its short half-life, Penicillin G is administered in divided doses, usually every 4 to 6 hours with the exception of meningococcal meningitis/septicemia, i.e., every 2 hours. Pediatric Patients This product should not be administered to patients requiring less than one million units per dose. (see PRECAUTIONS: Pediatric Use ). Renal Impairment Penicillin G is relatively nontoxic, and dosage adjustments are generally required only in cases of severe renal impairment. The recommended dosage regimens are as follows: Creatinine clearance less than 10 mL/min/1.73 m 2 ; administer a full loading dose (see recommended dosages in the tables above) followed by one-half of the loading dose every 8 to 10 hours. Uremic patients with a creatinine clearance greater than 10 mL/min/1.73m 2 ; administer a full loading dose (see recommended dosages in the tables above) followed by one-half of the loading dose every 4 to 5 hours. Additional dosage modifications should be made in patients with hepatic disease and renal impairment. For most acute infections, treatment should be continued for at least 48 to 72 hours after the patient becomes asymptomatic. Antibiotic therapy for Group A β-hemolytic streptococcal infections should be maintained for at least 10 days to reduce the risk of rheumatic fever. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Preparation of Solution Solutions of penicillin should be prepared as follows: Loosen powder. Hold vial horizontally and rotate it while slowly directing the stream of diluent against the wall of the vial. Shake vial vigorously after all the diluent has been added. Depending on the route of administration, use Sterile Water for Injection, USP, 0.9% Sodium Chloride Injection, USP, or Dextrose Injections, USP. Note: Penicillins are rapidly inactivated in the presence of carbohydrate solutions at alkaline pH. PREPARATION OF SOLUTION – 5 million units Diluent Added Final Concentration 8 mL 500,000 units/mL 3 mL 1,000,000 units/mL"],"spl_product_data_elements":["Penicillin G Sodium Penicillin G Sodium PENICILLIN G SODIUM PENICILLIN G"],"indications_and_usage_table":["<table width=\"100%\"> <col width=\"49%\"/> <col width=\"51%\"/> <thead> <tr> <th align=\"left\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <content styleCode=\"bold\">Clinical Indication</content> </th> <th align=\"left\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <content styleCode=\"bold\">Infecting Organism</content> </th> </tr> </thead> <tbody> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Septicemia, empyema,</paragraph> <paragraph>pneumonia, pericarditis,</paragraph> <paragraph>endocarditis, meningitis</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"italics\">Streptococcus pyogenes</content> </paragraph> <paragraph>(group A &#x3B2;-hemolytic</paragraph> <paragraph>streptococcus), other</paragraph> <paragraph>&#x3B2;-hemolytic streptococci</paragraph> <paragraph>including groups C, H, G, L</paragraph> <paragraph>and M, <content styleCode=\"italics\">Streptococcus</content> </paragraph> <paragraph> <content styleCode=\"italics\">pneumoniae</content> and</paragraph> <paragraph> <content styleCode=\"italics\">Staphylococcus</content> species (non-</paragraph> <paragraph>penicillinase producing strains)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Anthrax</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"italics\">Bacillus anthracis</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Actinomycosis (cervico-</paragraph> <paragraph>facial disease and</paragraph> <paragraph>thoracic and abdominal</paragraph> <paragraph>disease)</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"italics\">Actinomyces Israelil</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Botulism (adjunctive</paragraph> <paragraph>therapy to antitoxin),</paragraph> <paragraph>gas gangrene, and</paragraph> <paragraph>tetanus (adjunctive</paragraph> <paragraph>therapy to human</paragraph> <paragraph>tetanus immune globulin)</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"italics\">Clostridium species</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Diphtheria (adjunctive</paragraph> <paragraph>therapy to antitoxin and</paragraph> <paragraph>prevention of the carrier</paragraph> <paragraph>state)</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"italics\">Corynebacterium</content> </paragraph> <paragraph> <content styleCode=\"italics\">diphtheriae</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Erysipelothrix</paragraph> <paragraph> endocarditis</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"italics\">Erysipelothrix</content> </paragraph> <paragraph> <content styleCode=\"italics\">rhusiopthiae</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Fusospirochetosis</paragraph> <paragraph>(severe infections of the</paragraph> <paragraph>oropharynx [Vincent&#x2019;s],</paragraph> <paragraph>lower respiratory tract</paragraph> <paragraph>and genital area)</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"italics\">Fusobacterium species</content> </paragraph> <paragraph>and spirochetes</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Listeria infections</paragraph> <paragraph>including meningitis and</paragraph> <paragraph>endocarditis</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"italics\">Listeria monocytogenes</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Pasteurella infections</paragraph> <paragraph>including bacteremia and</paragraph> <paragraph>meningitis</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"italics\">Pasteurella multocida</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Haverhill fever</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"italics\">Streptobacillus</content> </paragraph> <paragraph> <content styleCode=\"italics\">moniliformis</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Rat-bite fever</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"italics\">Spirillum minus or</content> </paragraph> <paragraph> <content styleCode=\"italics\">Streptobacillus</content> </paragraph> <paragraph> <content styleCode=\"italics\">moniliformis</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Disseminated gonococcal</paragraph> <paragraph>infections</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"italics\">Neisseria gonorrhoeae</content> </paragraph> <paragraph> <content styleCode=\"italics\">(penicillin-susceptible)</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Syphilis (congenital and</paragraph> <paragraph>neurosyphilis)</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"italics\">Treponema pallidum</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Meningococcal</paragraph> <paragraph>meningitis and/or</paragraph> <paragraph>septicemia</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"italics\">Neisseria meningitidis</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>Gram-negative bacillary</paragraph> <paragraph>infections (bacteremias)</paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"italics\">Escherichia coli,</content> </paragraph> <paragraph> <content styleCode=\"italics\">Enterobacter aerogenes,</content> </paragraph> <paragraph> <content styleCode=\"italics\">Alcaligenes faecalis,</content> </paragraph> <paragraph> <content styleCode=\"italics\">salmonella, shigella</content> and</paragraph> <paragraph> <content styleCode=\"italics\">Proteus mirabilis,</content> Penicillin G</paragraph> <paragraph>is not the drug of choice in the</paragraph> <paragraph>treatment of gram-negative</paragraph> <paragraph>bacillary infections.</paragraph> </td> </tr> </tbody> </table>"],"dosage_and_administration_table":["<table width=\"100%\"> <col width=\"51%\"/> <col width=\"49%\"/> <thead> <tr> <th align=\"left\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <content styleCode=\"bold\">Clinical Indication</content> </th> <th align=\"left\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <content styleCode=\"bold\">Dosage</content> </th> </tr> </thead> <tbody> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Serious infections due to susceptible strains of</paragraph> <paragraph>streptococci (including <content styleCode=\"italics\">S. pneumoniae</content>) and</paragraph> <paragraph>staphylococci-septicemia, empyema, pneumonia,</paragraph> <paragraph>pericarditis, endocarditis and meningitis</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>5 to 24 million units/day depending on the infection and its severity administered in equally divided doses every 4 to 6 hours</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Anthrax</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>Minimum of 8 million units/day in divided doses every 6 hours. Higher doses may be required depending on susceptibility of organism.</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Actinomycosis</paragraph> <paragraph> Cervicofacial disease</paragraph> <paragraph> Thoracic and abdominal disease</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>1 to 6 million units/day(*)</paragraph> <paragraph>10 to 20 million units/day(*)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Clostridial infections</paragraph> <paragraph> Botulism (adjunctive therapy to antitoxin)</paragraph> <paragraph> Gas gangrene</paragraph> <paragraph> (debridement and/or surgery as indicated)</paragraph> <paragraph> Tetanus </paragraph> <paragraph> (adjunctive therapy to human tetanus</paragraph> <paragraph> immune globulin)</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>20 million units/day(*)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Diphtheria </paragraph> <paragraph>(adjunctive therapy to antitoxin and for the prevention of the carrier state)</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>2 to 3 million units/day in divided doses for 10 to</paragraph> <paragraph>12 days(*)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Erysipelothrix</paragraph> <paragraph>endocarditis</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>12 to 20 million units/day for 4 to 6 weeks(*)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Fusospirochetosis</paragraph> <paragraph>(severe infections of the oropharnyx [Vincent&#x2019;s], lower respiratory tract and genital area)</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>5 to 10 million units/day(*)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Listeria infections</paragraph> <paragraph> Meningitis</paragraph> <paragraph> Endocarditis</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>15 to 20 million units/day for 2 weeks(*)</paragraph> <paragraph>15 to 20 million units/day for 4 weeks(*)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Pasteurella infections including bacteremia and meningitis</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>4 to 6 million units/day for 2 weeks(*)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Haverhill fever, Rat-bite fever</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>12 to 20 million units/day for 3 to 4 weeks(*)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Disseminated gonococcal infections, such as meningitis endocarditis, arthritis, etc., caused by penicillin- susceptible organisms</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>10 million units/day(*);</paragraph> <paragraph>duration depends on the type of infection</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Syphilis (neurosyphilis)</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>12 to 24 million units/day, as 2 to 4 MU every 4 hours for 10 to 14 days; many experts recommend additional therapy with Benzathine PCN G 2.4 MU IM weekly for 3 doses after completion of</paragraph> <paragraph>IV therapy</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Meningococcal meningitis and/or septicemia</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>24 million units/day as 2 million units every 2 hours</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Serious infections, such as pneumonia and endocarditis, due to susceptible strains of</paragraph> <paragraph> <content styleCode=\"italics\">streptococci</content> (including <content styleCode=\"italics\">S. pneumoniae</content>) and</paragraph> <paragraph>meningococcus</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>150,000 units/kg/day divided in equal doses every</paragraph> <paragraph>4 to 6 hours; duration depends on infecting organism and type of infection</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Meningitis caused by susceptible strains of pneumococcus and meningococcus</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>250,000 units/kg/day divided in equal doses every</paragraph> <paragraph>4 hours for 7 to 14 days depending on the infecting</paragraph> <paragraph>organism (maximum dose of 12 to 20 million units/day)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Disseminated Gonococcal infections (penicillin-susceptible strains)</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>weight less than 45 kg:</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> Arthritis</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>100,000 units/kg/day in 4 equally divided doses for 7 to 10 days</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> Meningitis</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>250,000 units/kg/day in equal doses every 4 hours for 10 to 14 days</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> Endocarditis</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>250,000 units/kg/day in equal doses every 4 hours</paragraph> <paragraph>for 4 weeks</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Arthritis, meningitis, endocarditis</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>weight 45 kg or greater:</paragraph> <paragraph>10 million units/day in 4 equally divided doses with the duration of therapy depending on the type of infection</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Syphilis (congenital and neurosyphilis) after the</paragraph> <paragraph>newborn period</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>200,000 to 300,000 units/kg/day (administered as</paragraph> <paragraph>50,000 units/kg every 4 to 6 hours) for 10 to 14 days</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Diphtheria (adjunctive therapy to antitoxin and for prevention of the carrier state)</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>150,000 to 250,000 units/kg/day in equal doses</paragraph> <paragraph>every 6 hours for 7 to 10 days</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>Rat-bite fever; Haverhill fever (with endocarditis caused by <content styleCode=\"italics\">S. moniliformis</content>)</paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>150,000 to 250,000 units/kg/day in equal doses</paragraph> <paragraph>every 4 hours for 4 weeks</paragraph> </td> </tr> </tbody> </table>","<table width=\"100%\"> <caption>PREPARATION OF SOLUTION &#x2013; 5 million units</caption> <col width=\"49%\"/> <col width=\"51%\"/> <thead> <tr> <th align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <content styleCode=\"bold\">Diluent Added</content> </th> <th align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"top\"> <content styleCode=\"bold\">Final Concentration</content> </th> </tr> </thead> <tbody> <tr> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>8 mL </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Toprule Botrule \" valign=\"top\"> <paragraph>500,000 units/mL</paragraph> </td> </tr> <tr> <td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"> <paragraph>3 mL </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"> <paragraph>1,000,000 units/mL</paragraph> </td> </tr> </tbody> </table>"],"package_label_principal_display_panel":["5,000,000 Unit Vial Label NDC 0781-6153-95 Penicillin G Sodium for Injection, USP 5,000,000 Units* (5 million units) Rx Only For IM or IV use 10 Vials SANDOZ 5-million-case-label"],"drug_and_or_laboratory_test_interactions":["Drug/Laboratory Test Interactions After treatment with penicillin G, a false-positive reaction for glucose in the urine may occur with Benedict’s solution, Fehling’s solution or Clinitest® tablet, but not with the enzyme-based tests, such as Clinistix® and Tes-Tape®. Penicillin G has been associated with pseudoproteinuria by certain test methods."],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term animal studies have been conducted with this drug."]},"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DRUG HYPERSENSITIVITY","source":"FDA FAERS","actionTaken":"510 reports"},{"date":"","signal":"HYPERSENSITIVITY","source":"FDA FAERS","actionTaken":"280 reports"},{"date":"","signal":"RASH","source":"FDA FAERS","actionTaken":"87 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"70 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"67 reports"},{"date":"","signal":"CONDITION AGGRAVATED","source":"FDA FAERS","actionTaken":"46 reports"},{"date":"","signal":"DRUG INTOLERANCE","source":"FDA FAERS","actionTaken":"45 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"43 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"42 reports"},{"date":"","signal":"URTICARIA","source":"FDA FAERS","actionTaken":"40 reports"}],"drugInteractions":[{"drug":"chloramphenicol","severity":"major","mechanism":"antagonizes the bactericidal effect of penicillin","management":"avoid concurrent use","clinicalEffect":"reduced efficacy of penicillin"},{"drug":"erythromycins","severity":"major","mechanism":"antagonizes the bactericidal effect of penicillin","management":"avoid concurrent use","clinicalEffect":"reduced efficacy of penicillin"},{"drug":"sulfonamides","severity":"major","mechanism":"antagonizes the bactericidal effect of penicillin","management":"avoid concurrent use","clinicalEffect":"reduced efficacy of penicillin"},{"drug":"tetracyclines","severity":"major","mechanism":"antagonizes the bactericidal effect of penicillin","management":"avoid concurrent use","clinicalEffect":"reduced efficacy of penicillin"},{"drug":"probenecid","severity":"moderate","mechanism":"blocks renal tubular secretion of penicillins","management":"monitor penicillin levels and adjust dose if necessary","clinicalEffect":"prolonged penicillin blood levels"},{"drug":"aspirin","severity":"moderate","mechanism":"competes with penicillin G for renal tubular secretion","management":"monitor penicillin levels and adjust dose if necessary","clinicalEffect":"prolonged serum half-life of penicillin"},{"drug":"phenylbutazone","severity":"moderate","mechanism":"competes with penicillin G for renal tubular secretion","management":"monitor penicillin levels and adjust dose if necessary","clinicalEffect":"prolonged serum half-life of penicillin"},{"drug":"indomethacin","severity":"moderate","mechanism":"competes with penicillin G for renal tubular secretion","management":"monitor penicillin levels and adjust dose if necessary","clinicalEffect":"prolonged serum half-life of penicillin"},{"drug":"thiazide diuretics","severity":"moderate","mechanism":"competes with penicillin G for renal tubular secretion","management":"monitor penicillin levels and adjust dose if necessary","clinicalEffect":"prolonged serum half-life of penicillin"},{"drug":"furosemide","severity":"moderate","mechanism":"competes with penicillin G for renal tubular secretion","management":"monitor penicillin levels and adjust dose if necessary","clinicalEffect":"prolonged serum half-life of penicillin"},{"drug":"ethacrynic acid","severity":"moderate","mechanism":"competes with penicillin G for renal tubular secretion","management":"monitor penicillin levels and adjust dose if necessary","clinicalEffect":"prolonged serum half-life of penicillin"}],"commonSideEffects":[]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=PENICILLIN G SODIUM","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T04:24:12.614019+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T04:24:19.326510+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T04:24:11.230951+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PENICILLIN G SODIUM","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T04:24:20.025739+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T04:24:10.207271+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T04:26:54.971651+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T04:24:10.207313+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T04:24:22.037257+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Bacterial penicillin-binding protein inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T04:24:21.105785+00:00"},"safety.drugInteractions":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T04:25:09.369696+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1126/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T04:24:21.012139+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA065068","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T04:24:10.207318+00:00"}},"_dailymed":{"setId":"049b289b-3813-4d06-90d7-0d31c0b34977","title":"ALBADRY PLUS (NOVOBIOCIN SODIUM AND PENICILLIN G PROCAINE) INJECTION, SOLUTION [ZOETIS INC.]"},"_scrapedAt":"2026-03-28T00:33:28.940Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T04:26:55.232892+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"id":"penicillin-g-sodium-septicemia","name":"Septicemia","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with septicemia","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with septicemia","diagnosticRequired":"Culture and susceptibility tests","brandNameForIndication":""},{"id":"penicillin-g-sodium-empyema","name":"Empyema","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with empyema","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with empyema","diagnosticRequired":"Culture and susceptibility tests","brandNameForIndication":""},{"id":"penicillin-g-sodium-pneumonia","name":"Pneumonia","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with pneumonia","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with pneumonia","diagnosticRequired":"Culture and susceptibility tests","brandNameForIndication":""},{"id":"penicillin-g-sodium-pericarditis","name":"Pericarditis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with pericarditis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with pericarditis","diagnosticRequired":"Culture and susceptibility tests","brandNameForIndication":""},{"id":"penicillin-g-sodium-endocarditis","name":"Endocarditis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with endocarditis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with endocarditis","diagnosticRequired":"Culture and susceptibility tests","brandNameForIndication":""},{"id":"penicillin-g-sodium-meningitis","name":"Meningitis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with meningitis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with meningitis","diagnosticRequired":"Culture and susceptibility tests","brandNameForIndication":""},{"id":"penicillin-g-sodium-anthrax","name":"Anthrax","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with anthrax","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with anthrax","diagnosticRequired":"Culture and susceptibility tests","brandNameForIndication":""},{"id":"penicillin-g-sodium-actinomycosis","name":"Actinomycosis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with actinomycosis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with actinomycosis","diagnosticRequired":"Culture and susceptibility tests","brandNameForIndication":""},{"id":"penicillin-g-sodium-botulism","name":"Botulism","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with botulism","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with botulism","diagnosticRequired":"Culture and susceptibility tests","brandNameForIndication":""},{"id":"penicillin-g-sodium-gas-gangrene","name":"Gas Gangrene","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with gas gangrene","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with gas gangrene","diagnosticRequired":"Culture and susceptibility tests","brandNameForIndication":""},{"id":"penicillin-g-sodium-tetanus","name":"Tetanus","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with tetanus","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with tetanus","diagnosticRequired":"Culture and susceptibility tests","brandNameForIndication":""},{"id":"penicillin-g-sodium-diphtheria","name":"Diphtheria","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with diphtheria","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with diphtheria","diagnosticRequired":"Culture and susceptibility tests","brandNameForIndication":""},{"id":"penicillin-g-sodium-erysipelothrix-endocarditis","name":"Erysipelothrix Endocarditis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with erysipelothrix endocarditis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with erysipelothrix endocarditis","diagnosticRequired":"Culture and susceptibility tests","brandNameForIndication":""},{"id":"penicillin-g-sodium-fusospirochetosis","name":"Fusospirochetosis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with fusospirochetosis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with fusospirochetosis","diagnosticRequired":"Culture and susceptibility tests","brandNameForIndication":""},{"id":"penicillin-g-sodium-listeria-infections","name":"Listeria Infections","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with listeria infections","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with listeria infections","diagnosticRequired":"Culture and susceptibility tests","brandNameForIndication":""},{"id":"penicillin-g-sodium-pasteurella-infections","name":"Pasteurella Infections","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with pasteurella infections","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with pasteurella infections","diagnosticRequired":"Culture and susceptibility tests","brandNameForIndication":""},{"id":"penicillin-g-sodium-haverhill-fever","name":"Haverhill Fever","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with haverhill fever","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with haverhill fever","diagnosticRequired":"Culture and susceptibility tests","brandNameForIndication":""},{"id":"penicillin-g-sodium-rat-bite-fever","name":"Rat-Bite Fever","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with rat-bite fever","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with rat-bite fever","diagnosticRequired":"Culture and susceptibility tests","brandNameForIndication":""},{"id":"penicillin-g-sodium-disseminated-gonococcal-infect","name":"Disseminated Gonococcal Infections","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with disseminated gonococcal infections","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with disseminated gonococcal infections","diagnosticRequired":"Culture and susceptibility tests","brandNameForIndication":""},{"id":"penicillin-g-sodium-syphilis","name":"Syphilis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with syphilis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with syphilis","diagnosticRequired":"Culture and susceptibility tests","brandNameForIndication":""},{"id":"penicillin-g-sodium-meningococcal-meningitis-and/o","name":"Meningococcal Meningitis and/or Septicemia","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with meningococcal meningitis and/or septicemia","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with meningococcal meningitis and/or septicemia","diagnosticRequired":"Culture and susceptibility tests","brandNameForIndication":""},{"id":"penicillin-g-sodium-gram-negative-bacillary-infect","name":"Gram-Negative Bacillary Infections","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with gram-negative bacillary infections","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with gram-negative bacillary infections","diagnosticRequired":"Culture and susceptibility tests","brandNameForIndication":""}]},"trialDetails":[{"nctId":"NCT07498153","phase":"NA","title":"Spotting Syphilis: A Dual Point-of-Care Syphilis Screening Initiative in a Low-Resource Healthcare Setting","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2025-09-30","conditions":"Syphilis, HIV Infections","enrollment":149},{"nctId":"NCT07207876","phase":"","title":"Study of Ceftriaxone and Benzathine Penicillin G During Pregnancy","status":"RECRUITING","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2026-02-16","conditions":"Pregnancy","enrollment":110},{"nctId":"NCT07492134","phase":"PHASE2","title":"APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis)","status":"NOT_YET_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2026-04-01","conditions":"Acute Uncomplicated Diverticulitis","enrollment":100},{"nctId":"NCT06977841","phase":"NA","title":"Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Zhongshan Hospital (Xiamen), Fudan University","startDate":"2025-06-10","conditions":"Helicobacter Pylori Eradication, Adverse Reaction","enrollment":640},{"nctId":"NCT05761080","phase":"PHASE4","title":"Fast Track Therapeutic Model in Acute Complicated Appendicitis in Pediatrics","status":"RECRUITING","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2021-04-22","conditions":"Laparoscopic Appendectomy, Complicated Appendicitis, Periappendicular Abscess","enrollment":772},{"nctId":"NCT04948463","phase":"PHASE4","title":"Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2021-11-15","conditions":"Febrile Neutropenia","enrollment":55},{"nctId":"NCT07484633","phase":"PHASE4","title":"A Randomised Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients.","status":"NOT_YET_RECRUITING","sponsor":"Semmelweis University","startDate":"2026-04","conditions":"Infection, Sepsis, NICU","enrollment":110},{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":"Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections","enrollment":300},{"nctId":"NCT06406114","phase":"PHASE2","title":"Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-05-05","conditions":"Drug Allergy, Cephalosporin Allergy, Drug Hypersensitivity","enrollment":300},{"nctId":"NCT07481539","phase":"PHASE2","title":"Subcutaneous Piperacillin/Tazobactam Compared With Intravenous Treatment","status":"RECRUITING","sponsor":"Azienda Sanitaria Universitaria Friuli Centrale","startDate":"2026-03-24","conditions":"Bacteria Infection, Piperacillin, Tazobactam Drug Combination","enrollment":240},{"nctId":"NCT07483736","phase":"PHASE3","title":"Efficacy of an Empirical Treatment With Amoxicillin-clavulanate (AC) Compared to the Combination Amoxicillin-clavulanate and Ciprofloxacin (AC+C) in the Outpatient Care of Chemotherapy-induced Fever in Adult Haematology Patients.","status":"NOT_YET_RECRUITING","sponsor":"Versailles Hospital","startDate":"2026-03","conditions":"C15.378","enrollment":1526},{"nctId":"NCT05693545","phase":"PHASE2","title":"GOALIE: Intramuscular vs. Enteral Penicillin Prophylaxis to Prevent Progression of Latent RHD Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2023-09-01","conditions":"Rheumatic Heart Disease","enrollment":1004},{"nctId":"NCT06154174","phase":"NA","title":"Choline to Improve Malnutrition and Enhance Cognition","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-12-05","conditions":"Severe Acute Malnutrition, Cognitive Impairment, Wasting","enrollment":1500},{"nctId":"NCT06712641","phase":"PHASE4","title":"Aminoglycosides in Early Sepsis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Akershus","startDate":"2026-04","conditions":"Sepsis","enrollment":1900},{"nctId":"NCT05548426","phase":"PHASE2","title":"Linezolid for Syphilis Pilot Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2023-09-28","conditions":"Syphilis","enrollment":24},{"nctId":"NCT05834036","phase":"PHASE4","title":"Effect of Antibiotics on Enteric Neurons and Glia","status":"COMPLETED","sponsor":"Rockefeller University","startDate":"2023-06-23","conditions":"Antibiotic Enterocolitis","enrollment":10},{"nctId":"NCT00713947","phase":"PHASE4","title":"Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control","status":"WITHDRAWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-04","conditions":"Positive Helicobacter Pylori Serology, Coronary Thrombosis, Supra-aortic Artery Thrombosis","enrollment":""},{"nctId":"NCT07457385","phase":"PHASE4","title":"Congenital Syphilis Treatment Trial (CONSISTENT) in Neonates","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-11-01","conditions":"Syphilis, Congenital","enrollment":374},{"nctId":"NCT07451171","phase":"PHASE2","title":"Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children","status":"NOT_YET_RECRUITING","sponsor":"University of Virginia","startDate":"2026-04","conditions":"Small Intestine Bacterial Overgrowth","enrollment":60},{"nctId":"NCT03078010","phase":"PHASE2","title":"Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-02-10","conditions":"Intestinal Microbiome, Febrile Neutropenia","enrollment":347},{"nctId":"NCT06076304","phase":"PHASE4","title":"Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis","status":"RECRUITING","sponsor":"Daniel Merenstein","startDate":"2023-11-21","conditions":"Sinus Infection, Acute Sinusitis","enrollment":3720},{"nctId":"NCT06494072","phase":"PHASE4","title":"Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2024-08-22","conditions":"Community Acquired Pneumonia in Children","enrollment":236},{"nctId":"NCT04514653","phase":"PHASE2","title":"RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-08-25","conditions":"Neovascular Age-Related Macular Degeneration (nAMD)","enrollment":146},{"nctId":"NCT05980871","phase":"PHASE4","title":"Treatment Responses of Early Syphilis to Ceftriaxone Plus Doxycycline","status":"TERMINATED","sponsor":"National Taiwan University Hospital","startDate":"2023-03-10","conditions":"Early Syphilis","enrollment":109},{"nctId":"NCT05398679","phase":"PHASE4","title":"Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":"Endocarditis Infective","enrollment":360},{"nctId":"NCT05894954","phase":"PHASE3","title":"Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Alzheimer's Prevention and Reversal Project, Inc.","startDate":"2023-07-31","conditions":"Mild Cognitive Impairment, Dementia, Mild","enrollment":73},{"nctId":"NCT06340724","phase":"PHASE3","title":"Banxiaxiexin Decoction Combined With Vonoprazan-Amoxicillin Dual Therapy in H. Pylori Eradication","status":"COMPLETED","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2024-02-15","conditions":"Helicobacter Pylori Infection","enrollment":104},{"nctId":"NCT06156085","phase":"PHASE4","title":"Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy","status":"COMPLETED","sponsor":"Fu Jen Catholic University Hospital","startDate":"2023-11-14","conditions":"Helicobacter Pylori Infection","enrollment":337},{"nctId":"NCT06954129","phase":"PHASE4","title":"A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2026-01-28","conditions":"Acute Kidney Injury","enrollment":750},{"nctId":"NCT07293910","phase":"PHASE2","title":"Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"Tanta University","startDate":"2026-02-15","conditions":"HELICOBACTER PYLORI INFECTIONS, Helicobacter Infection, Helicobacter Pylori Gastrointestinal Tract Infection","enrollment":66},{"nctId":"NCT02701595","phase":"PHASE3","title":"Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Streptococcus","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2016-02-29","conditions":"Infective Endocarditis","enrollment":324},{"nctId":"NCT03511118","phase":"","title":"Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants","status":"RECRUITING","sponsor":"Duke University","startDate":"2018-10-04","conditions":"Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI","enrollment":1600},{"nctId":"NCT06123169","phase":"PHASE3","title":"Postoperative Anti-infective Strategy Following Pancreaticoduodenectomy in Patients With Preoperative Biliary Stent","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2026-04","conditions":"Pancreaticoduodenectomy, Antibiotherapy","enrollment":326},{"nctId":"NCT05100654","phase":"EARLY_PHASE1","title":"Collaborative Urological Prosthetics Investigation Directive Research Group","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2022-04-22","conditions":"Erectile Dysfunction, Penile Prosthesis Infection","enrollment":800},{"nctId":"NCT04986254","phase":"","title":"PNEUmonia DOSing in Critically Ill Patients (PNEUDOS)","status":"COMPLETED","sponsor":"The University of Queensland","startDate":"2019-10-17","conditions":"Pneumonia","enrollment":179},{"nctId":"NCT06396078","phase":"PHASE4","title":"Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT)","status":"RECRUITING","sponsor":"Ohio State University","startDate":"2024-07-18","conditions":"Preterm Premature Rupture of Membrane, Pregnancy, High Risk, Preterm Birth","enrollment":56},{"nctId":"NCT06229288","phase":"PHASE3","title":"Amoxicillin Alone Versus Amoxicillin/Clavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, and Hospitalized in a Non-intensive Care Unit Ward","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-04-25","conditions":"Community-acquired Pneumonia","enrollment":326},{"nctId":"NCT06510010","phase":"PHASE2","title":"Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2024-12-31","conditions":"Chemotherapy Effect","enrollment":198},{"nctId":"NCT07358130","phase":"NA","title":"Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy","status":"RECRUITING","sponsor":"Kaohsiung Medical University","startDate":"2025-10-21","conditions":"Helicobacter Pylori Infection","enrollment":552},{"nctId":"NCT06426836","phase":"NA","title":"Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2016-08-19","conditions":"Pharmacokinetics, Amoxicillin-clavulanate, Piperacillin-tazobactam","enrollment":300},{"nctId":"NCT05647278","phase":"PHASE4","title":"Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for H. Pylori Infection (TATH-1)","status":"COMPLETED","sponsor":"Zhang Xiaofeng,MD","startDate":"2023-11-01","conditions":"Helicobacter Pylori Infection","enrollment":370},{"nctId":"NCT06349486","phase":"NA","title":"Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication","status":"RECRUITING","sponsor":"Kaohsiung Medical University","startDate":"2023-11-28","conditions":"Helicobacter Pylori Eradication","enrollment":390},{"nctId":"NCT02783859","phase":"PHASE4","title":"Hospitalised Pneumonia With Extended Treatment (HOPE) Study","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2016-06","conditions":"Pneumonia","enrollment":314},{"nctId":"NCT04549311","phase":"PHASE3","title":"Perianal Abscess Recurrence and Fistula Formation: Antibiotics Following Incision and Drainage Trial","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2021-11-18","conditions":"Perianal Abscess, Perianal Fistula","enrollment":15},{"nctId":"NCT07015736","phase":"PHASE4","title":"Effects of Saccharomyces Boulardii CNCM I-745 on Antibiotic-Associated Perturbation in Children Treated for Acute Respiratory Infections (RESTORE Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eskisehir Osmangazi University","startDate":"2025-08-01","conditions":"Antibiotic Associated Diarrhea, Acute Otitis Media, ACUTE SINUSITIS","enrollment":100},{"nctId":"NCT07294846","phase":"PHASE1","title":"Drug Interaction Study on Linaprazan Glurate Capsules","status":"COMPLETED","sponsor":"Jiangsu Sinorda Biomedicine Co., Ltd","startDate":"2025-09-08","conditions":"Healthy Volunteers, Patients","enrollment":56},{"nctId":"NCT05079620","phase":"PHASE4","title":"Early Antibiotics After Aspiration in ICU Patients","status":"TERMINATED","sponsor":"UConn Health","startDate":"2021-11-30","conditions":"Aspiration, Aspiration Pneumonia","enrollment":5},{"nctId":"NCT07296302","phase":"NA","title":"Antibiotic Prophylaxis Versus Placebo in Alveolar Bone Grafting: A Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Agnaldo Rocha de Souza Junior","startDate":"2026-02","conditions":"Alveolar Ridge Augmentation, Bone Grafting, Antibiotic Prophylaxis","enrollment":150},{"nctId":"NCT07304882","phase":"PHASE3","title":"A Comparison of Recovery After Impacted Wisdom Tooth Removal","status":"COMPLETED","sponsor":"University of Science and Technology, Yemen","startDate":"2023-11-30","conditions":"Impacted Mandibular Third Molar Extraction, Post Operative Complications","enrollment":24},{"nctId":"NCT07275827","phase":"PHASE3","title":"Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori Infection","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2026-02-01","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":88},{"nctId":"NCT02281929","phase":"PHASE3","title":"Efficacy of Antibiotic Therapy in Severe Alcoholic Hepatitis Treated With Prednisolone","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2015-06-13","conditions":"Alcoholic Hepatitis, Alcoholic Liver Disease","enrollment":297},{"nctId":"NCT07183462","phase":"PHASE4","title":"Azithromycin and Ampicillin for Late PPROM","status":"RECRUITING","sponsor":"Sheba Medical Center","startDate":"2025-09-10","conditions":"Pregnancy Complications, Infectious, Premature Birth, Neonatal Diseases and Abnormalities","enrollment":311},{"nctId":"NCT06869850","phase":"NA","title":"Milk Fat Globule Membrane-Enhanced RUTF for Children With Severe Acute Malnutrition","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-09-22","conditions":"Severe Acute Malnutrition, Cognitive Impairment, Kwashiorkor","enrollment":1600},{"nctId":"NCT05309928","phase":"PHASE1","title":"Phase 1 Study of the Pharmacokinetics of Amoxicillin in Pregnancy","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2023-08-29","conditions":"Pregnancy Related","enrollment":13},{"nctId":"NCT05926804","phase":"NA","title":"A \"Screen and Treat\" Helicobacter Pylori Eradication Trial in Adolescents in Three Regions of Chile","status":"RECRUITING","sponsor":"Miguel O'Ryan Gallardo","startDate":"2022-08-02","conditions":"Helicobacter Pylori Infection","enrollment":500},{"nctId":"NCT07275580","phase":"PHASE4","title":"Antibiotic Prophylaxis After Simple Tooth Extraction in Immunosuppressed Patients With Autoimmune Rheumatic Diseases","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-01-10","conditions":"Autoimmune Rheumatic Diseases, Tooth Extraction, Infection Prevention","enrollment":352},{"nctId":"NCT04350502","phase":"NA","title":"Pharmacokinetics and Pleural Fluid Penetration of Amoxicillin and Clavulanic Acid in Patients With Pleural Infections","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2019-07-18","conditions":"Pleural Infection, Empyema, Community-acquired Pneumonia","enrollment":11},{"nctId":"NCT05206500","phase":"PHASE4","title":"NextGen - Clinical Implication of Next Generation Sequencing","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2022-05-17","conditions":"Urinary Tract Infections","enrollment":100},{"nctId":"NCT06751121","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2024-02-06","conditions":"Helicobacter Pylori Infection, Helicobacter Pylori Infected Patients, Helicobacter Pylori Infected Subjects","enrollment":461},{"nctId":"NCT06734260","phase":"PHASE3","title":"Optimization of Keverprazan-amoxicillin Dual Therapy for Eradicating Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"Eighth Affiliated Hospital, Sun Yat-sen University","startDate":"2024-09-10","conditions":"Helicobacter Pylori Eradication Rate","enrollment":477},{"nctId":"NCT04876131","phase":"PHASE4","title":"Single Dose Intravenous Antibiotics for Complicated Urinary Tract Infections in Children","status":"RECRUITING","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-05-30","conditions":"Complicated Urinary Tract Infection, Infection, Pediatric Infectious Disease","enrollment":452},{"nctId":"NCT07260006","phase":"NA","title":"Treatment Efficacy of Regimens With and Without Bismuth in Children With Helicobacter Pylori-Associated Peptic Ulcer Disease","status":"RECRUITING","sponsor":"Can Tho University of Medicine and Pharmacy","startDate":"2024-10-01","conditions":"Helicobacter Pylori Infection, Peptic Ulcer","enrollment":80},{"nctId":"NCT06823154","phase":"PHASE1","title":"The Implementation and Impact of an Allergy De-Labeling Program in the Emergency Department","status":"ENROLLING_BY_INVITATION","sponsor":"The Hospital for Sick Children","startDate":"2023-11-27","conditions":"Allergy Amoxicillin, Beta-lactam Allergy Labels","enrollment":500},{"nctId":"NCT06126731","phase":"PHASE1, PHASE2","title":"Combination Study of Antibiotics With Enzalutamide (PROMIZE)","status":"RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2023-11-02","conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":39},{"nctId":"NCT07242456","phase":"PHASE2, PHASE3","title":"Head-to-head Study of Tegoprazan 50 mg BID Plus Amoxicillin 1 g TID vs. Vonoprazan 20 mg BID Plus Amoxicillin 1 g TID for H. Pylori Eradication","status":"RECRUITING","sponsor":"First People's Hospital of Hangzhou","startDate":"2025-02-17","conditions":"Helicobacter Pylori Infection","enrollment":240},{"nctId":"NCT07242443","phase":"PHASE4","title":"Tegoprazan Plus Amoxicillin BID vs TID Regimens for H. Pylori Eradication（Frequency Adjusted Same-dose Therapy for H. Pylori）","status":"NOT_YET_RECRUITING","sponsor":"First People's Hospital of Hangzhou","startDate":"2025-11-20","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":240},{"nctId":"NCT04838717","phase":"PHASE3","title":"Clinical Trial of Doxycycline VS BPG for Early Syphilis (SY-DOXY)","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-12-06","conditions":"Syphilis","enrollment":200},{"nctId":"NCT02473263","phase":"PHASE3","title":"Samu Save Sepsis: Early Goal Directed Therapy in Pre Hospital Care of Patients With Severe Sepsis and/or Septic Shock","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-05-09","conditions":"Severe Septic Syndrome (Severe Sepsis and Septic Shock) Diagnosed and Treated by Mobile Intensive Care Unit","enrollment":398},{"nctId":"NCT01543334","phase":"","title":"Antibiotic Concentrations Among Critically Ill Patients","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2012-03","conditions":"Administration of Antibiotics in Intensive Care Units","enrollment":98},{"nctId":"NCT06069141","phase":"NA","title":"Comparisons of Treatment Responses of Early Syphilis to Benzathine Penicillin G With or Without Doxycycline","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-01-01","conditions":"Early Syphilis, Latent, Serological Relapse After Treatment","enrollment":688},{"nctId":"NCT07189208","phase":"PHASE2","title":"Evaluation of Antimicrobial Prophylaxis to Prevent Syphilis in Pregnancy in Patients at Risk in Rio de Janeiro, Brazil","status":"RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2025-11-01","conditions":"Congenital Syphilis","enrollment":500},{"nctId":"NCT07233733","phase":"NA","title":"A Clinical Study of Connective Tissue Graft and Enamel Matrix Derivative in the Treatment of Intrabony Periodontal Defects","status":"COMPLETED","sponsor":"Phạm Đình Thiên Khải","startDate":"2024-06-01","conditions":"Periodontal Diseases, Regeneration","enrollment":17},{"nctId":"NCT03269994","phase":"PHASE3","title":"Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-11-21","conditions":"Pancreatic Cancer, Pancreas Cancer, Pancreatic Diseases","enrollment":967},{"nctId":"NCT05137119","phase":"PHASE4","title":"Staphylococcus Aureus Network Adaptive Platform Trial","status":"RECRUITING","sponsor":"University of Melbourne","startDate":"2022-02-16","conditions":"Staphylococcus Aureus Bacteremia","enrollment":8000},{"nctId":"NCT05846399","phase":"PHASE4","title":"CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE)","status":"RECRUITING","sponsor":"University of Missouri-Columbia","startDate":"2023-09-07","conditions":"Cat Bite, Hand Injuries, Arm Injury","enrollment":72},{"nctId":"NCT06010719","phase":"PHASE4","title":"Azithromycin as Adjunctive Treatment for Uncomplicated Severe Acute Malnutrition","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-10-23","conditions":"Malnutrition, Child, Severe Acute Malnutrition","enrollment":3000},{"nctId":"NCT07202091","phase":"PHASE2, PHASE3","title":"Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)","status":"RECRUITING","sponsor":"Monash University","startDate":"2025-05-06","conditions":"Myeloma, Leukemia, Non Hodgkin&#39;s Lymphoma","enrollment":900},{"nctId":"NCT07202052","phase":"PHASE2, PHASE3","title":"Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)","status":"RECRUITING","sponsor":"Monash University","startDate":"2025-05-06","conditions":"Myeloma, Non-Hodgkin's Lymphoma, Leukemia","enrollment":900},{"nctId":"NCT07096310","phase":"PHASE1, PHASE2","title":"Comparison Between Carbapenems and Noncarbapenem Beta-lactam Antibiotics in Septic Burn Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ain Shams University","startDate":"2024-01-01","conditions":"Sepsis","enrollment":400},{"nctId":"NCT06368102","phase":"PHASE4","title":"Prophylactic Effects for Preventing Surgical Site Infection in Third Molar Surgery","status":"COMPLETED","sponsor":"Uji Takeda Hospital","startDate":"2024-05-02","conditions":"Surgical Site Infection","enrollment":70},{"nctId":"NCT03997266","phase":"PHASE4","title":"NICU Antibiotics and Outcomes Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Michael Morowitz","startDate":"2020-08-05","conditions":"Microbial Colonization, Extreme Prematurity, Early-Onset Neonatal Sepsis","enrollment":802},{"nctId":"NCT05332444","phase":"PHASE4","title":"Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2022-04-11","conditions":"Helicobacter Pylori Infection","enrollment":450},{"nctId":"NCT01015417","phase":"PHASE3","title":"Place of Antibiotics in the Postoperative Acute Lithiasic Cholecystitis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2010-05","conditions":"Acute Lithiasic Cholecystitis Grade I or II, Symptoms Lasting for Less Than 5 Days, Required Cholecystectomy","enrollment":414},{"nctId":"NCT04728516","phase":"PHASE4","title":"The Effect of Dual Eradication Therapy vs PPI on Gastrointestinal Bleeding in ACS Patients","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2023-04-12","conditions":"Acute Coronary Syndrome, Helicobacter Pylori Infection","enrollment":2600},{"nctId":"NCT05874544","phase":"PHASE4","title":"Rescue Therapy for Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2023-05-16","conditions":"Helicobacter Pylori Infection","enrollment":360},{"nctId":"NCT02707042","phase":"PHASE1","title":"Microbial, Immune, and Metabolic Perturbations by Antibiotics (MIME Study)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-03-22","conditions":"Normal Physiology, Healthy","enrollment":108},{"nctId":"NCT07148622","phase":"NA","title":"Effects of Different Antibiotic Regimens in Preterm Premature Rupture of Membranes","status":"COMPLETED","sponsor":"Yuzuncu Yil University","startDate":"2024-10-01","conditions":"Preterm Premature Rupture of Membranes (PPROM), Prophylaxis, Perinatal Outcomes","enrollment":40},{"nctId":"NCT06451913","phase":"PHASE4","title":"Effect of Saccharomyces Boulardii CNCM I-745 on Gut Microbiota in Patients Undergoing Antibiotic Therapy (in the Context of Erythema Migrans (Early Skin Form of Lyme Borreliosis))","status":"RECRUITING","sponsor":"Biocodex","startDate":"2025-07-16","conditions":"Erythema Migrans of Lyme Disease","enrollment":120},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT05464615","phase":"EARLY_PHASE1","title":"Geisinger Antibiotic Allergy Pilot Program: Assess and Address","status":"RECRUITING","sponsor":"Geisinger Clinic","startDate":"2024-03-04","conditions":"Penicillin Allergy","enrollment":100},{"nctId":"NCT03273296","phase":"PHASE4","title":"Effect of Antibiotics on Gut Microbiome and Plasma Metabolome","status":"COMPLETED","sponsor":"Finnish Institute for Health and Welfare","startDate":"2017-10-15","conditions":"Microbial Colonization","enrollment":39},{"nctId":"NCT05857163","phase":"PHASE3","title":"Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection","status":"COMPLETED","sponsor":"TenNor Therapeutics (Suzhou) Limited","startDate":"2023-05-18","conditions":"H.Pylori Infection","enrollment":700},{"nctId":"NCT07122024","phase":"PHASE4","title":"Efficacy and Safety of Keverprazan-amoxicillin Dual Therapy for Helicobacter Pylori First-line Treatment","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-02-19","conditions":"Helicobacter Pylori","enrollment":414},{"nctId":"NCT07068607","phase":"PHASE4","title":"Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradication: A Prospective, Randomized Controlled Clinical Trial","status":"RECRUITING","sponsor":"Yongquan Shi","startDate":"2025-04-01","conditions":"Gastritis, Indigestion, Helicobacter Pylori Infection, Gastric Cancer, Peptic Ulcer","enrollment":400},{"nctId":"NCT07115173","phase":"PHASE4","title":"Clinical Trial to Evaluate the Efficacy of Probit-Based Triple Therapy for Helicobacter Pylori Eradication","status":"NOT_YET_RECRUITING","sponsor":"Samsung Medical Center","startDate":"2025-12-01","conditions":"Helicobacter Infection","enrollment":103},{"nctId":"NCT06131021","phase":"PHASE3","title":"Shaping the Indications for Periodontal Adjunctive Antibiotics in Dental Practice","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2024-04-25","conditions":"Periodontitis, Periodontal Diseases, Periodontal Pocket","enrollment":150},{"nctId":"NCT07107477","phase":"PHASE3","title":"TAILORED Therapeutic Regime in Patients With Preterm Premature Rupture Of Membranes to Prolong Pregnancy, Improve Maternal and Neonatal Outcomes, and Reduce Antibiotic Burden","status":"RECRUITING","sponsor":"The Central and Eastern European Gynecologic Oncology Group","startDate":"2025-05-01","conditions":"Preterm Premature Rupture of Membranes (PPROM)","enrollment":138},{"nctId":"NCT05469984","phase":"NA","title":"Comparing Two Prophylactic Antibiotic Protocols in Women With Term Prolonged Pre-labor Rupture of Membrane and Preterm Labor","status":"RECRUITING","sponsor":"Western Galilee Hospital-Nahariya","startDate":"2022-11-25","conditions":"Preterm Labor With Preterm Delivery, Premature Rupture of Membranes Prolonged","enrollment":600},{"nctId":"NCT06771492","phase":"PHASE3","title":"Efficacy of Antibiotic Treatment for Patients With Chronic Low Back Pain and Modic Type I Changes - Randomized Placebo-controlled Trial","status":"RECRUITING","sponsor":"Bart Koes","startDate":"2025-04-02","conditions":"MSK Conditions, Chronic Low Back Pain (CLBP), Modic Changes","enrollment":204},{"nctId":"NCT03671967","phase":"PHASE4","title":"PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)","status":"RECRUITING","sponsor":"Rambam Health Care Campus","startDate":"2019-05-01","conditions":"Beta Lactam Resistant Bacterial Infection, Enterobacteriaceae Infections, Bacteremia","enrollment":1084}],"_emaApprovals":[],"_faersSignals":[],"administration":{"route":"Intramuscular"},"crossReferences":{"chemblId":"CHEMBL1126"},"_approvalHistory":[],"publicationCount":96,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"approved","brandName":"PENICILLIN G SODIUM","genericName":"PENICILLIN G SODIUM","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1982","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2004-09-30T00:00:00.000Z","mah":"SANDOZ","brand_name_local":null,"application_number":"ANDA065068"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T04:26:55.232892+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}